News | August 09, 2022
Indraprastha Medical Corporation posts Q1 FY23 PAT at Rs. 20.28 Cr
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 264.09 crores during the period ended June 30, 2022.
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
Under the PMBJP, till 30.06.2022, 8742 PMBJKs have been opened across the country including Government Hospitals and Government premises.
Health resources – both human and material are precious assets to the society and a robust health care administration and management system ensures their effective utilization: Dr Bharati Pravin Pawar
The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
The product will be manufactured at Lupin's facility in Nagpur, India.
Subscribe To Our Newsletter & Stay Updated
